Trial Profile

Investigating the clinical use of 13-valent pneumococcal conjugate vaccine (Prevenar) in childhood acute lymphoblastic leukaemia

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
Indications Pneumococcal infections
Focus Pharmacodynamics
Acronyms PCV13 in ALL

Most Recent Events

05 Oct 2019 Results published in the Clinical Infectious Diseases
06 Dec 2013 Accrual to date is 85% according to United Kingdom Clinical Research Network.
23 Nov 2013 Accrual to date is 84% according to United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com